Pfizer’s Lorbrena Outperforms Xalkori in 5-Year ALK-Positive NSCLC Follow-Up
Pfizer Inc. (NYSE: PFE) has announced the release of five-year follow-up data for its kinase...
NYSE: PFE
Pfizer Pauses Dosing in DMD Gene Therapy Trial Following Participant’s Sudden Death
This week, Pfizer Inc. (NYSE: PFE) announced the unfortunate sudden death of a participant in...
Pfizer Appoints Citigroup’s Andrew Baum as Executive Vice-President for Strategy and Innovation
Pfizer Inc. (NYSE: PFE) has announced the appointment of Andrew Baum, M.D., to serve as...
Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability
Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of...
Pfizer’s Gene Therapy Beqvez Wins FDA Nod for Moderate-to-Severe Hemophilia B
The US Food and Drug Administration (FDA) has granted marketing authorization to Pfizer (NYSE: PFE)...
European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications
The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam +...
Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults
Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...
Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma
The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...
Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...
European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...
Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial
Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis
The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points...
Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results
Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...
Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...
Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines
Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...